{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=54&q=small+cell+lung+cancer", "query": { "q": "small cell lung cancer", "condition": "Lung Cancer", "page": 54 }, "page_size": 10 }, "pagination": { "page": 54, "page_size": 10, "total_count": 4379, "total_pages": 438, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=55&q=small+cell+lung+cancer&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=53&q=small+cell+lung+cancer&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T21:20:32.045Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03237377", "title": "Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Thoracic Radiation", "type": "RADIATION" }, { "name": "lobectomy", "type": "PROCEDURE" }, { "name": "Standard of care adjuvant chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 9, "start_date": "2017-12-12", "completion_date": "2024-05-23", "has_results": true, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03237377" }, { "nct_id": "NCT02941601", "title": "A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Squamous Non-Small Cell Lung Cancer", "Metastatic Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Necitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-11", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2019-09-27", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 1, "location_summary": "Edina, Minnesota", "locations": [ { "city": "Edina", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02941601" }, { "nct_id": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Neoplasms", "Uterine Cervical Neoplasms", "Biliary Tract Neoplasms", "Urologic Neoplasms", "Carcinoma, Non-Small-Cell Lung", "HER2 Mutations Breast Neoplasms" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2021-01-11", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 76, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04579380" }, { "nct_id": "NCT04025879", "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2019-11-05", "completion_date": "2027-07-31", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 15, "location_summary": "Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04025879" }, { "nct_id": "NCT00042679", "title": "A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Pulmonary Neoplasms", "Neoplasms, Lung" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "LY900003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-07-19", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 11, "location_summary": "Bakersfield, California • Berkeley, California • Torrance, California + 8 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042679" }, { "nct_id": "NCT06225427", "title": "Gilteritinib for the Treatment of ALK NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-07-25", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 3, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06225427" }, { "nct_id": "NCT00451022", "title": "Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer", "Liver Cancer", "Breast Cancer", "Colon Cancer", "Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2004-09-13", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00451022" }, { "nct_id": "NCT00405951", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Obatoclax mesylate 250 ml", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gemin X", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2006-10", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2016-07-21", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405951" }, { "nct_id": "NCT03996473", "title": "Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY 88-8223)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-03-06", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 1, "location_summary": "San Marcos, California", "locations": [ { "city": "San Marcos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03996473" }, { "nct_id": "NCT00094094", "title": "Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Neoplasms", "Carcinoma, Non-small Cell Lung" ], "interventions": [ { "name": "axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2005-02", "completion_date": "2007-07", "has_results": true, "last_update_posted_date": "2012-06-26", "last_synced_at": "2026-10-19T21:20:32.045Z", "location_count": 10, "location_summary": "Irvine, California • Orange, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Coon Rapids", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094094" } ] }